Table 1. Patient characteristics... | American Society of Hematology

Table 1.

Patient characteristics

Characteristic	All patients (N = 54)				Feasibility cohort (n = 21)
Characteristic	No.	%	Median	Range	No.	%	Median	Range
Age, y			75	23-90			76	55-87
Sex
Male	41	76			15	71
Female	13	24			6	29
Diagnosis
AML	10	19			1	5
De novo AML	4	7			0	0
Secondary AML*	6	11			1	5
MDS	33	61			17	81
Lower-risk MDS (IPSS-R <4)	12	22			5	24
Higher-risk MDS (IPSS-R ≥4)	21	39			12	57
MDS/MPN	11	20			3	14
CMML	4	7			1	5
Other MDS/MPN	7	13			2	9
Prognostic factor
Adverse cytogenetics or mutations†	28	52			11	52
Bone marrow blast percent			8	1-90			5	1-31
No. of mutations‡			2	0-6			2	0-6
Frequent mutations
TET2	12	22			5	24
ASXL1	11	20			5	24
DNMT3A	10	19			4	19
STAG2	9	17			5	24
SF3B1	9	17			2	10
RUNX1	8	15			4	19
BCOR	8	15			2	10
NRAS	8	15			1	5
SRSF2	7	13			4	19
KRAS	7	13			2	10
TP53	6	11			1	5
EZH2	5	9			2	10
CEBPA	5	9			2	10
U2AF1	4	7			2	10
JAK2 V617F	3	6			1	5
FLT3-ITD	3	6			0	0
Previous HMA therapy
Yes	32	59			21	100
No	22	41			0	0

Characteristic	All patients (N = 54)				Feasibility cohort (n = 21)
Characteristic	No.	%	Median	Range	No.	%	Median	Range
Age, y			75	23-90			76	55-87
Sex
Male	41	76			15	71
Female	13	24			6	29
Diagnosis
AML	10	19			1	5
De novo AML	4	7			0	0
Secondary AML*	6	11			1	5
MDS	33	61			17	81
Lower-risk MDS (IPSS-R <4)	12	22			5	24
Higher-risk MDS (IPSS-R ≥4)	21	39			12	57
MDS/MPN	11	20			3	14
CMML	4	7			1	5
Other MDS/MPN	7	13			2	9
Prognostic factor
Adverse cytogenetics or mutations†	28	52			11	52
Bone marrow blast percent			8	1-90			5	1-31
No. of mutations‡			2	0-6			2	0-6
Frequent mutations
TET2	12	22			5	24
ASXL1	11	20			5	24
DNMT3A	10	19			4	19
STAG2	9	17			5	24
SF3B1	9	17			2	10
RUNX1	8	15			4	19
BCOR	8	15			2	10
NRAS	8	15			1	5
SRSF2	7	13			4	19
KRAS	7	13			2	10
TP53	6	11			1	5
EZH2	5	9			2	10
CEBPA	5	9			2	10
U2AF1	4	7			2	10
JAK2 V617F	3	6			1	5
FLT3-ITD	3	6			0	0
Previous HMA therapy
Yes	32	59			21	100
No	22	41			0	0

CMML, chronic myelomonocytic leukemia.

Includes patients with an antecedent myeloid neoplasm or therapy-related AML.

†

For MDS and MDS/MPNs, adverse cytogenetics were defined by IPSS-R and adverse mutations included TP53, EZH2, ETV6, RUNX1, and ASXL1; for AML, adverse cytogenetics and mutations were defined by the 2017 European LeukemiaNet criteria.

‡

Includes pathogenic and likely pathogenic mutations and excludes variants of unknown significance.

View Large

This Feature Is Available To Subscribers Only